UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~February~~May 2831, 2026

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from [ ] to [ ]

Commission file number 001-39874

LEXARIA BIOSCIENCE CORP.

(Exact name of registrant as specified in its charter)

Nevada		20-2000871
(State or other jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

#100 – 740 McCurdy Road, Kelowna BC Canada		V1X 2P7
(Address of principal executive offices)		(Zip Code)

Registrant’s Telephone number, including area code: 1.250.765.6424

Securities registered pursuant to Section 12(b) of the Act:

Title of Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, Par Value $0.001	LEXX	The NASDAQ Capital Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the last 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by a check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

24,787,446 common shares issued as of ~~April~~July 13, 2026

DOCUMENTS INCORPORATED BY REFERENCE

None.

TABLE OF CONTENTS

PART I—FINANCIAL INFORMATION		3
Item 1. Financial Statements		3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		20
Item 4. Controls and Procedures.		30
PART II—OTHER INFORMATION		31
Item 1. Legal Proceedings		31
Item 1A. Risk Factors		31
Item 2. Recent Sales of Unregistered Equity Securities		32
Item 3. 10b5-1 Trading Plans		32
Item 4. Exhibits, Financial Statement Schedules		3233

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

LEXARIA BIOSCIENCE CORP.

LEXARIA BIOSCIENCE CORP.
CONSOLIDATED BALANCE SHEETS
(Expressed in US Dollars)
(Unaudited)

	May 31,			August 31,
	2026			2025
ASSETS
Current
Cash	$	3,475,003		$	1,802,123
Short-term investments		142,103			143,267
Marketable securities		-			22,093
Accounts receivable		48,998			368,358
Prepaid expenses and other current assets		398,765			1,132,504
Total Current Assets		4,064,869			3,468,345

Non-current assets, net
Long-term receivables		64,014			64,013
Right of use assets		84,415			106,816
Intellectual property, net		339,016			307,818
Property & equipment, net		229,017			228,129
Total Non-current Assets		716,462			706,776

TOTAL ASSETS	$	4,781,331		$	4,175,121

LIABILITIES and STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable and accrued liabilities	$	350,377		$	1,463,046
Lease liability, current		33,035			30,417
Total Current Liabilities		383,412			1,493,463

Lease liabilities - non-current		53,679			78,903

TOTAL LIABILITIES	$	437,091		$	1,572,366

Stockholders' Equity
Share Capital
Authorized: 220,000,000 common voting shares with a par value of $0.001 per share Common shares issued and outstanding: 24,787,446 and 19,559,179 at May 31, 2026 and August 31, 2025, respectively	$	24,788		$	19,559
Additional paid-in capital		73,256,696			66,501,086
Accumulated Deficit		(68,496,801	)		(63,460,613	)
Accumulated other comprehensive loss		(46,473	)		(70,335	)
Equity attributable to shareholders of Lexaria		4,738,210			2,989,697
Non-controlling Interest		(393,970	)		(386,942	)
Total Stockholders' Equity		4,344,240			2,602,755
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	4,781,331		$	4,175,121

CONSOLIDATED BALANCE SHEETS

(Expressed in US Dollars)

(Unaudited)

	February 28,			August 31,
	2026			2025
ASSETS
Current
Cash	$	5,128,141		$	1,802,123
Short-term investments		141,266			143,267
Marketable securities		-			22,093
Accounts receivable		42,029			368,358
Prepaid expenses and other current assets		458,846			1,132,504
Total Current Assets		5,770,282			3,468,345
Non-current assets, net
Long-term receivables		64,014			64,013
Right of use assets		92,018			106,816
Intellectual property, net		318,058			307,818
Property & equipment, net		242,931			228,129
Total Non-current Assets		717,021			706,776
TOTAL ASSETS	$	6,487,303		$	4,175,121
LIABILITIES and STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable and accrued liabilities	$	182,611		$	1,463,046
Lease liability, current		32,060			30,417
Total Current Liabilities		214,671			1,493,463
Lease liabilities - non-current		62,326			78,903
TOTAL LIABILITIES	$	276,997		$	1,572,366
Stockholders' Equity
Share Capital
Authorized: 220,000,000 common voting shares with a par value of $0.001 per share Common shares issued and outstanding:
24,887,446 and 19,559,179 at February 28, 2026 and August 31, 2025, respectively	$	24,888		$	19,559
Additional paid-in capital		73,138,652			66,501,086
Accumulated Deficit		(66,505,599	)		(63,460,613	)
Accumulated other comprehensive loss		(55,444	)		(70,335	)
Equity attributable to shareholders of Lexaria		6,602,497			2,989,697
Non-controlling Interest		(392,191	)		(386,942	)
Total Stockholders' Equity		6,210,306			2,602,755
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	6,487,303		$	4,175,121

The accompanying notes are an integral part of these unaudited interim consolidated financial statements.

Table of Contents

LEXARIA BIOSCIENCE CORP.

LEXARIA BIOSCIENCE CORP.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Expressed in US Dollars except share amounts)
(Unaudited)

	Three Months Ended						Nine Months Ended
	May 31,			May 31,			May 31,			May 31,
	2026			2025			2026			2025

Revenue	$	-		$	174,000		$	20,000		$	531,923
Cost of goods sold		-			-			-			2,720
Gross profit		-			174,000			20,000			529,203

Operating expenses
Research and development		970,834			2,717,501			2,117,562			6,356,637
General and administrative		1,022,970			1,206,920			2,921,776			3,364,706
Total operating expenses		1,993,804			3,924,421			5,039,338			9,721,343

Loss from operations		(1,993,804	)		(3,750,421	)		(5,019,338	)		(9,192,140	)

Other income (loss)
Interest income		837			190			2,618			201
Unrealized loss on marketable securities		-			(40,375	)		(22,093	)		(22,267	)
Total other income (loss)		837			(40,185	)		(19,475	)		(22,066	)

Net loss before income taxes	$	(1,992,967	)	$	(3,790,606	)	$	(5,038,813	)	$	(9,214,206	)
Income taxes		14			-			4,403			-
Net loss	$	(1,992,981	)	$	(3,790,606	)	$	(5,043,216	)	$	(9,214,206	)
Less: Net loss attributable to non-controlling interest		(1,779	)		(1,514	)		(7,028	)		(8,203	)
Net loss attributable to Lexaria shareholders	$	(1,991,202	)	$	(3,789,092	)	$	(5,036,188	)	$	(9,206,003	)

Other comprehensive income
Foreign currency translation adjustment		8,971			37,173			23,862			(61,257	)
Total comprehensive loss	$	(1,982,231	)	$	(3,751,919	)	$	(5,012,326	)	$	(9,267,260	)
Basic and diluted loss per share	$	(0.08	)	$	(0.21	)	$	(0.21	)	$	(0.53	)

Weighted average number of common shares outstanding
Basic and diluted		24,805,924			18,298,309			23,543,278			17,472,844

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Expressed in US Dollars except share amounts)

(Unaudited)

	Three Months Ended						Six Months Ended
	February 28,			February 28,			February 28,			February 28,
	2026			2025			2026			2025
Revenue	$	20,000		$	174,000		$	20,000		$	357,923
Cost of goods sold		-			-			-			2,720
Gross profit		20,000			174,000			20,000			355,203
Operating expenses
Research and development		475,388			1,685,916			1,146,728			3,639,136
General and administrative		996,515			1,239,096			1,898,806			2,157,786
Total operating expenses		1,471,903			2,925,012			3,045,534			5,796,922
Loss from operations		(1,451,903	)		(2,751,012	)		(3,025,534	)		(5,441,719	)
Other income (loss)
Interest income		1,769			-			1,781			11
Unrealized gain (loss) on marketable securities		-			34,040			(22,093	)		18,108
Total other income (loss)		1,769			34,040			(20,312	)		18,119
Net loss before income taxes	$	(1,450,134	)	$	(2,716,972	)	$	(3,045,846	)	$	(5,423,600	)
Income taxes		2,598			-			4,389			-
Net loss	$	(1,452,732	)	$	(2,716,972	)	$	(3,050,235	)	$	(5,423,600	)
Less: Net loss attributable to non-controlling interest		(2,753	)		(3,760	)		(5,249	)		(6,689	)
Net loss attributable to Lexaria shareholders	$	(1,449,979	)	$	(2,713,212	)	$	(3,044,986	)	$	(5,416,911	)
Other comprehensive income
Foreign currency translation adjustment		20,635			(95,255	)		14,891			(98,430	)
Total comprehensive loss	$	(1,429,344	)	$	(2,808,467	)	$	(3,030,095	)	$	(5,515,341	)
Basic and diluted loss per share	$	(0.06	)	$	(0.15	)	$	(0.13	)	$	(0.32	)
Weighted average number of common shares outstanding
Basic and diluted		24,443,846			17,511,908			22,901,491			17,065,084

The accompanying notes are an integral part of these unaudited interim consolidated financial statements.

Table of Contents

LEXARIA BIOSCIENCE CORP.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

For the ~~Six~~Nine Months Ended ~~February~~May 2831, 2026 and 2025

(Expressed in US Dollars)

(Unaudited)

							Additional								Non-
	Common Stock						Paid-in								controlling			Stockholders'
	Shares			Amount			Capital		Deficit			AOCI			Interest			Equity
Balance August 31, 2025		19,559,179		$	19,559		$	66,501,086	$	(63,460,613	)	$	(70,335	)	$	(386,942	)	$	2,602,755
Shares sold for cash		2,666,667			2,667			3,446,384		-			-			-			3,449,051
Stock-based compensation		-			-			74,895		-			-			-			74,895
Foreign currency translation adjustment		-			-			-		-			(5,744	)		-			(5,744	)
Net loss		-			-			-		(1,595,007	)		-			-			(1,595,007	)
Non-controlling interest		-			-			-		-			-			(2,496	)		(2,496	)
Balance November 30, 2025		22,225,846		$	22,226		$	70,022,365	$	(65,055,620	)	$	(76,079	)	$	(389,438	)	$	4,523,454
Shares sold for cash		2,661,600			2,662			3,041,392		-			-			-			3,044,054
Stock-based compensation		-			-			74,895		-			-			-			74,895
Foreign currency translation adjustment		-			-			-		-			20,635			-			20,635
Net loss		-			-			-		(1,449,979	)		-			-			(1,449,979	)
Non-controlling interest		-			-			-		-			-			(2,753	)		(2,753	)
Balance February 28, 2026		24,887,446		$	24,888		$	73,138,652	$	(66,505,599	)	$	(55,444	)	$	(392,191	)	$	6,210,306
Cancellation of RSA shares		(100,000	)		(100	)		100		-			-			-			-
Stock-based compensation		-			-			92,944		-			-			-			92,944
Foreign currency translation adjustment		-			-			-		-			8,971			-			8,971
Reclassification of deferred offering costs		-			-			25,000		-			-			-			25,000
Net loss		-			-			-		(1,991,202	)		-			-			(1,991,202	)
Non-controlling interest		-			-			-		-			-			(1,779	)		(1,779	)
Balance May 31, 2026		24,787,446		$	24,788		$	73,256,696	$	(68,496,801	)	$	(46,473	)	$	(393,970	)	$	4,344,240
Balance August 31, 2024		15,810,205		$	15,810		$	59,599,178	$	(51,558,772	)	$	(19,816	)	$	(377,349	)	$	7,659,051
Shares sold for cash		1,642,389			1,643			4,343,750		-			-			-			4,345,393
Stock-based compensation		-			-			99,415		-			-			-			99,415
Foreign currency translation adjustment		-			-			-		-			(3,175	)		-			(3,175	)
Net loss		-			-			-		(2,703,699	)		-			-			(2,703,699	)
Non-controlling interest		-			-			-		-			-			(2,929	)		(2,929	)
Balance November 30, 2024		17,452,594		$	17,453		$	64,042,343	$	(54,262,471	)	$	(22,991	)	$	(380,278	)	$	9,394,056
Shares sold for cash		6,585			6			11,714		-			-			-			11,720
Stock-based compensation		100,000			100			167,119		-			-			-			167,219
Foreign currency translation adjustment		-			-			-		-			(95,255	)		-			(95,255	)
Net loss		-			-			-		(2,713,212	)		-			-			(2,713,212	)
Non-controlling interest		-			-			-		-			-			(3,760	)		(3,760	)
Balance February 28, 2025		17,559,179		$	17,559		$	64,221,176	$	(56,975,683	)	$	(118,246	)	$	(384,038	)	$	6,760,768
Shares sold for cash		2,000,000			2,000			1,687,050		-			-			-			1,689,050
Stock-based compensation		-			-			470,136		-			-			-			470,136
Foreign currency translation adjustment		-			-			-		-			37,173			-			37,173
Net loss		-			-			-		(3,789,092	)		-			-			(3,789,092	)
Non-controlling interest		-			-			-		-			-			(1,514	)		(1,514	)
Balance May 31, 2025		19,559,179		$	19,559		$	66,378,362	$	(60,764,775	)	$	(81,073	)	$	(385,552	)	$	5,166,521

The accompanying notes are an integral part of these unaudited interim consolidated financial statements.

Table of Contents

CONSOLIDATED STATEMENTS OF CASH FLOWS

LEXARIA BIOSCIENCE CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Nine Months Ended May 31, 2026 and 2025
(Expressed in US Dollars)
(Unaudited)

	May 31,			May 31,
	2026			2025
Cash flows used in operating activities
Net loss	$	(5,043,216	)	$	(9,214,206	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation		242,734			736,770
Depreciation and amortization		55,175			66,427
Impairment loss		-			33,540
Noncash lease expense		22,401			20,828
Unrealized loss on marketable securities		22,093			22,267
Lease accretion		5,403			6,977
Change in operating assets and liabilites
Accounts receivable		319,360			(203,652	)
Prepaid expenses and deposits		733,739			364,469
Long-term receivables		(1	)		(439	)
Accounts payable and accrued liabilities		(1,112,669	)		391,850
Operating lease liability		(28,009	)		(27,757	)
Deferred revenue		-			(4,963	)
Net cash used in operating activities	$	(4,782,990	)	$	(7,807,889	)

Cash flows used in investing activities
Short-term investments	$	1,164		$	-
Additions to intellectual property		(46,445	)		(60,496	)
Purchase of equipment		(40,816	)		(24,645	)
Net cash used in investing activities	$	(86,097	)	$	(85,141	)

Cash flows from/(used in) financing activities
Proceeds from shares sold for cash	$	6,518,105		$	6,046,163
Net cash from/(used in) financing activities	$	6,518,105		$	6,046,163

Effect of exchange rate changes on cash	$	23,862		$	(61,257	)
Net change in cash for the period		1,672,880			(1,908,124	)
Cash at beginning of period		1,802,123			6,499,885
Cash at end of period	$	3,475,003		$	4,591,761

Supplemental cash flow disclosure:
Income taxes paid in cash	$	4,403		$	-
Non-cash investing/financing activities:
Cancellation of RSA shares	$	100		$	-

For the Six Months Ended February 28, 2026 and 2025

(Expressed in US Dollars)

(Unaudited)

	February 28,			February 28,
	2026			2025
Cash flows used in operating activities
Net loss	$	(3,050,235	)	$	(5,423,600	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation		149,790			266,634
Depreciation and amortization		35,967			35,472
Impairment loss		-			33,540
Noncash lease expense		14,798			13,759
Unrealized loss on marketable securities		22,093			(18,108	)
Lease accretion		3,739			4,778
Change in operating assets and liabilities
Accounts receivable		326,329			(176,688	)
Prepaid expenses and deposits		648,658			337,431
Long-term receivables		-			(439	)
Accounts payable and accrued liabilities		(1,280,437	)		726,669
Operating lease liability		(18,672	)		(18,421	)
Deferred revenue		-			(4,963	)
Net cash used in operating activities	$	(3,147,970	)	$	(4,223,936	)
Cash flows used in investing activities
Short-term investments	$	2,001			-
Additions to intellectual property		(20,193	)	$	(41,052	)
Purchase of equipment		(40,816	)		(24,646	)
Net cash used in investing activities	$	(59,008	)	$	(65,698	)
Cash flows from financing activities
Proceeds from shares sold for cash	$	6,518,105		$	4,357,113
Net cash from financing activities	$	6,518,105		$	4,357,113
Effect of exchange rate changes on cash	$	14,891		$	(98,430	)
Net change in cash for the period		3,326,018			(30,951	)
Cash at beginning of period		1,802,123			6,499,885
Cash at end of period	$	5,128,141		$	6,468,934
Supplemental cash flow disclosure:
Income taxes paid in cash	$	4,389		$	-
Non-cash investing/financing activities:
Amortization of deferred offering costs	$	25,000		$	-

The accompanying notes are an integral part of these unaudited interim consolidated financial statements.

Table of Contents

LEXARIA BIOSCIENCE CORP.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

~~February~~May 2831, 2026

(Expressed in U.S. Dollars Except Share Amounts)

(Unaudited)

1. Nature of Business

Lexaria Bioscience Corp. (“Lexaria”, “we”, “our” or “the Company”) is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“API”) using our proprietary DehydraTECH drug delivery technology. Our current focus is the investigation of the incorporation of our DehydraTECH drug delivery technology with GLP-1, GIP, and ~~GIP~~glucagon drugs to enhance absorption and reduce adverse side effects.

Revenues have historically been generated from licensing contracts for the Company’s patented DehydraTECH technology based on the terms of use and defined geographic and licensing arrangements. We derive revenue from our third party contracted manufacturing of B2B DehydraTECH enhanced products made to customer specifications that are sold online and in-store in the US and Canada. We have also performed contract services in R&D for customer specific formulations that are used in comparison testing to customers’ existing products.

Going Concern

The Company’s consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and in accordance with accounting principles generally accepted in the United States (“US GAAP”) applicable to a going concern, which assumes the Company will have sufficient funds to meet its financial obligations for a period of at least 12 months from the date of this report.

Since inception, the Company has incurred significant operating and net losses. Net losses attributable to shareholders were $~~3.0~~5 million and $59.42 million for the ~~six~~nine months ended ~~February~~May 2831, 2026, and ~~February~~May 2831, 2025, respectively. As of ~~February~~May 2831, 2026, we had an accumulated deficit of $6668.5 million. We expect to continue to incur significant operational expenses and net losses in the upcoming 12 months. Our net losses may fluctuate significantly from quarter to quarter and year to year, depending on the stage and complexity of our research and development (R&D) studies and corporate expenditures, additional revenues received from the licensing of our technology, if any, and the receipt of payments under any current or future collaborations into which we may enter. The recurring losses and negative net cash flows raise substantial doubt as to the Company’s ability to continue as a going concern.

During the ~~six~~nine months ended ~~February~~May 2831, 2026, we raised $6.5 million in net proceeds from the sale of securities pursuant to our Registered Direct Offerings which closed in September 2025 and December 2025.

We may offer securities in response to market conditions or other circumstances if we believe such a plan of financing is required to advance the Company’s business plans. There is no certainty that future equity or debt financing will be available or that it will be at acceptable terms, and the outcome of these matters is unpredictable. A lack of adequate funding may force us to reduce spending, curtail or suspend planned programs, or possibly liquidate assets. Any of these actions could adversely and materially affect our business, cash flow, financial condition, results of operations, and potential prospects. The sale of additional equity may result in additional dilution to our stockholders. Entering into additional licensing agreements, collaborations, partnerships, alliances marketing, distribution, or licensing arrangements with third parties to increase our capital resources is also possible. If we do so, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us.

Our ability to continue operations after our current cash resources are exhausted is dependent on our ability to obtain additional debt or equity financing or a strategic partnership, which cannot be guaranteed. Cash requirements may vary materially from those now planned because of changes in our focus and direction of our research and development programs, competitive and technical advances, patent developments, regulatory changes or other developments. If adequate additional funds are not available when required, management may need to curtail its development efforts and planned operations to conserve cash.

Table of Contents

As of ~~February~~May 2831, 2026, the Company had cash and cash equivalents of approximately $53.15 million to settle $0.24 million in current liabilities. We have performed a review of our cash flow forecast, and given our current development plans and cash management efforts, we anticipate that our cash resources will be sufficient to fund operations through the first quarter of fiscal year 2027. However, we have also concluded that our existing cash, combined with inflows expected from executed license agreements, will not be sufficient to meet the Company's financial obligations for the twelve-month period following the issuance of these consolidated financial statements. Accordingly, there is substantial doubt as to our ability to continue as a going concern within one year from the date of issuance of these financial statements. The accompanying financial statements do not include any adjustments that might be necessary if the Company is not able to continue as a going concern.

2. Significant Accounting Policies

The significant accounting policies of the Company are consistent with those of our audited financial statements on Form 10-K for the year ended August 31, 2025.

Basis of Consolidation

These unaudited interim consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries: Lexaria CanPharm ULC, Lexaria CanPharm Holding Corp., PoViva Corp., Lexaria Hemp Corp., Kelowna Management Services Corp., Lexaria Nutraceutical Corp., Lexaria (AU) Pty Ltd., and Lexaria Pharmaceutical Corp., and our 83.333% owned subsidiary Lexaria Nicotine LLC with the remaining 16.667% owned by Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc. All significant intercompany balances and transactions have been eliminated upon consolidation.

Basis of Presentation

The Company’s unaudited interim consolidated financial statements have been prepared pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally accepted accounting principles (US GAAP) have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results for a full year or for any subsequent period.

These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated annual financial statements and notes thereto included in our annual report filed on Form 10-K for the year ended August 31, 2025.

Cash and Cash Equivalents

Cash and cash equivalents include cash-on-hand and demand deposits with financial institutions and other short-term investments with maturities of less than ~~six~~three months when acquired and readily convertible to known cash amounts. The Company had no cash equivalents as of ~~February~~May 2831, 2026, or August 31, 2025.

Short-term investments

Short-term investment balances consist of guaranteed investment certificates used to secure the Company’s credit cards. The certificates had an original term of one year.

Marketable Securities

The Company’s marketable securities consist of investments in common stock. Investments in equity securities are reported at fair value with changes in unrecognized gains or losses included in other income (loss) on the Consolidated Statements of Operations and Comprehensive Loss. There have been no purchases or sales of equity securities. The Company recognized an unrealized loss on its equity securities of $22,093 for the ~~six~~nine months ended ~~February~~May 2831, 2026 and an unrealized ~~gain~~loss of $1822,~~108~~267 for the ~~six~~nine months ended ~~February~~May 2831, 2025.

Table of Contents

Leases

The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are reported on the consolidated balance sheet as both a right-of-use asset and lease liability.

We determined the initial classification and measurement of our right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that we are reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, we use our incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that we would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment.

Operating lease expenses are recognized on a straight-line basis, unless the right-of-use asset has been impaired, over the reasonably certain lease term based on the total lease payments. They are included in operating expenses in the Consolidated Statements of Operations and Comprehensive Loss.

For operating leases that reflect impairment, we will recognize the amortization of the right-of-use asset on a straight-line basis over the remaining lease term with rent expense still included in operating expenses in the Consolidated Statements of Operations and Comprehensive Loss. For all leases, rent payments that are based on a fixed index or rate at the lease commencement date are included in the measurement of lease assets and lease liabilities at the lease commencement date.

We have elected the practical expedient to not separate lease and non-lease components. Our non-lease components are primarily related to property taxes and maintenance, which vary based on future outcomes, and thus differences to original estimates are recognized in rent expense when incurred.

Intellectual property

Capitalized intellectual property costs include those incurred with respect to both pending and granted patents filed in the United States. When patent applications are filed, the directly related capitalized costs are amortized on a straight-line basis over an estimated economic life of 20 years.

Property and equipment

Property and equipment is stated at cost less accumulated depreciation and impairment and depreciated using the straight-line method over the useful lives of the various asset classes. Laboratory and computer equipment and office furniture are depreciated over 3-10 years. Leasehold improvements are amortized over the term of the related leases, or the economic life of the improvements, whichever is shorter.

Impairment of long-lived assets

Long-lived assets, including equipment and intangible assets, namely the Company’s patents, are assessed for potential impairment when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Any required impairment loss is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value and is recorded as a reduction in the carrying value of the related asset and a charge to the profit or loss. Intangible assets with indefinite lives are tested for impairment annually and in interim periods if certain events occur indicating that the carrying value of the intangible assets may be impaired.

Table of Contents

Revenue recognition

The Company recognizes revenue in accordance with ASC 606’s core principle by applying the following five steps:

	1.	Identify contracts with customers
	2.	Identify the performance obligations in the contracts
	3.	Determine the contract price
	4.	Allocate the contract price
	5.	Recognize revenue when/as performance obligations are satisfied

Licensing revenue from intellectual property

Our revenues from licenses that grant exclusive rights to use our intellectual property, which we consider functional IP, are recognized at a point in time following the transfer and use of our patented infusion technology DehydraTECH. Our licensees are also required to pay quarterly fixed non-refundable minimum performance fees which are recognized as revenue over the period to which they apply.

Usage fees from intellectual property

The Company may also earn sales-based or usage-based royalties from its licensing contracts. The Company recognizes usage fees in the period when our licensees recognize sales of end-products that incorporate our licensed technology. No sales-based usage fees were recognized for the ~~six~~nine months ended ~~February~~May 2831, 2026 and ~~February~~May 2831, 2025.

Third Party Contracted Manufacturing

The Company recognizes revenue with respect to contract manufacturing arrangements when the related performance obligations have been satisfied (i.e., when it has completed the related manufacturing work) and in accordance with the five steps described in ASC 606.

Contract Research and Development

The Company recognizes revenue from contract research and development arrangements when the related performance obligations have been satisfied and in accordance with the five steps described in ASC 606. The related performance obligation typically entails preparation of customer-specific formulations (i.e., DehydraTECH paired with the customer’s active ingredient) that the customer then uses in comparison testing relative to its existing product(s). Revenue is recognized upon shipment of the formulation to the customer.

Cost of sales

Cost of sales includes all expenditures incurred in bringing the goods to the point of sale. This includes third-party manufacturing and handling costs, direct costs of raw material, inbound freight charges, warehousing costs, and applicable overhead expenses.

Research and development

Research and development costs are expensed as incurred. These expenditures are comprised of both in-house research programs and through third-party contracts including consultants, academic and non-profit institutions, contract manufacturing, and other expenses.

Australian Research and Development Tax Credit

The research and development incentive is one of the key elements of the Australian Government’s support for Australia’s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997, as long as eligibility criteria are met. Under the program, a percentage of eligible research and development expenses incurred by the Company through its Australian subsidiary are reimbursed. Management has assessed the Company’s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the incentive regime. The Company recognizes such benefits when both of the following conditions have been met: 1) the Company is able to comply with the relevant conditions of the credit and; 2) the credit has been received. The tax credit related to fiscal year spending for 2024 in the amount of $39,134 has been received and is included in our fiscal year 2025 financial statements. The tax credit related to fiscal year spending for 2025 has yet to be received and thus remains unrecorded as of this time.

Table of Contents

Australian Research and Development Tax Credit

The research and development incentive is one of the key elements of the Australian Government’s support for Australia’s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997, as long as eligibility criteria are met. Under the program, a percentage of eligible research and development expenses incurred by Lexaria (AU) Pty Ltd, the Company’s Australian subsidiary, are reimbursed. Management has assessed Lexaria (AU) Pty Ltd’s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the incentive regime. For the purposes of these consolidated financial statements, the Company recognizes such benefits when both of the following conditions have been met: 1) Lexaria (AU) Pty Ltd is able to comply with the relevant conditions of the credit and; 2) the credit has been received. The tax credit related to fiscal year spending for 2025 has yet to be received and thus remains unrecorded at this time.

Intellectual property expenses

Non-capitalizable costs associated with intellectual property-related matters are expensed as incurred and included in general and administrative expenses within the Consolidated Statements of Operations and Comprehensive Loss.

Stock-based compensation

The Company accounts for its stock-based compensation awards whereby all stock-based grants are recognized as expenses in the Consolidated Statements of Operations and Comprehensive Loss based on the fair value at grant date subject to vesting dates and amortized over the related vesting period. The grant date fair value of each option award is estimated using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected term of the option, risk-free interest rates and expected dividend yields of the common stock.

Foreign currency translation

The Company’s reporting currency is the U.S. dollar. The Company has foreign operations whose functional currency is the local currency. Assets and liabilities are translated into U.S. dollars, the reporting currency, at the exchange rate on the balance sheet date. Revenues and expenses are translated into U.S. dollars at the average rates of exchange prevailing during the reporting period. Foreign currency translation adjustments resulting from this process are reported as an element of other comprehensive income (loss) on the Consolidated Statements of Operations and Comprehensive Loss. Transactions executed in different currencies are translated at spot rates and resulting foreign exchange transaction gains and losses are charged to income.

Segment reporting

The Company has one reportable segment: IP licensing. The IP licensing segment generates revenue from customers by licensing its proprietary DehydraTECH technology. The IP licensing segment’s accounting policies are the same as those described in this note. The chief operating decision maker, our Chief Executive Officer, assesses performance of the IP Licensing segment and makes resource allocation decisions based on cash flows that are also reported on the Consolidated Statements of Cash Flows. The measure of segment assets is reported on the consolidated balance sheet as consolidated total assets. The measure of segment profit or loss is net loss as per the Consolidated Statements of Operations and Comprehensive Loss.

Loss per share

The calculation of loss per share uses the weighted average number of shares outstanding during the year. Diluted net income per share includes the effect, if any, from the potential exercise or conversion of securities, such as restricted stock, stock options, and warrants, which would result in the issuance of incremental shares of common stock. Diluted loss per share is equivalent to basic loss per share if the potential exercise of the equity-based financial instruments is anti-dilutive.

Table of Contents

For the ~~six~~nine months ended ~~February~~May 2831, 2026 and 2025, the following common stock equivalents were excluded from the computation of diluted loss per share as the result was anti-dilutive:

	February 28,
	May 31,
	2026		2025
Stock Options		1,~~476~~399,~~035~~535		1,~~070~~484,~~269~~435
Warrants		11,093,099		7,~~562~~298,~~028~~171
Totals		12,~~569~~492,~~134~~634		8,~~632~~782,~~297~~606

Income taxes

The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns using the liability method. Under this method, deferred tax liabilities and assets are determined based on the temporary differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the year in which the differences are expected to reverse. A valuation allowance is established to reduce deferred tax assets to an amount whose realization is more likely than not.

Fair value measurements

When measuring fair value, the Company seeks to maximize the use of observable inputs and minimize the use of unobservable inputs. This establishes a fair value hierarchy based on the level of independent objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Inputs are prioritized into three levels used to measure fair value:

	·	Level 1 - Quoted prices in active markets for identical assets or liabilities;

	·	Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and

	·	Level 3 - Unobservable inputs that are supported by little or no market activity, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.

The Company’s financial instruments consist primarily of cash, short-term investments, marketable securities, accounts receivable and payable as well as accrued liabilities. The carrying amounts of instruments approximate their fair values due to their short maturities or quoted market prices.

The Company’s headquarters are located in Canada, and it also has operations in Australia, which results in exposure to market risks from fluctuations in foreign currency rates. The foreign currency exchange risk is the financial risk to the Company’s operations that arise from fluctuations in foreign exchange rates and the degree of volatility of these rates. Currently, the Company does not use derivative instruments to reduce its exposure to foreign currency risk as the impact of USD/CAD and USD/AUD exchange rate changes is not expected to be material.

The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of ~~February~~May 2831, 2026.

Carrying

Fair Value Measurement Using

Value

Level 1

Level 2

Level 3

Total

Marketable Securities

12 Table of Contents

The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of August 31, 2025.

	Carrying		Fair Value Measurement Using
	Value		Level 1		Level 2		Level 3		Total
Marketable Securities	$	22,093	$	22,093	$	-	$	-	$	22,093

Table of Contents

Credit risk and customer concentration

The Company places its cash with a high credit quality financial institution. Periodically, the Company may carry cash balances at such financial institution in excess of the federally insured limit of $250,000. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant.

In the ~~six~~nine months ended ~~February~~May 2831, 2026, the Company recognized revenue of $20,000 on a consolidated basis. One customer accounted for 100% of that total. In the ~~six~~nine months ended ~~February~~May 2831, 2025, the Company recognized revenue of $~~357~~531,923 on a consolidated basis. Two customers accounted for 100% of that total.

As of ~~February~~May 2831, 2026, the Company had $4248,~~029~~998 in sales tax receivable, as compared to $194,358 as of August 31, 2025. The Company considers its credit risk to be low for such receivables.

Commitments and contingencies

The Company’s policy is to record accruals for any such loss contingencies when it is probable that a liability has been incurred, and the amount of loss can be reasonably estimated. In the event that estimates or assumptions prove to differ from actual results, adjustments are made in subsequent periods to reflect more current information. The Company, from time to time, may be subject to legal claims and proceedings related to matters arising in the ordinary course of business. Management has no knowledge of any such claim against the Company with, at minimum, a reasonable possibility that a material loss may be incurred.

3. Recent Accounting Guidance

Recently Adopted Pronouncements

In March 2024, the FASB issued ASU 2024-02-Codification Improvements-Amendments to Remove References to the Concepts Statements, that contains amendments to the Codification that remove references to various FASB Concepts Statements. This effort facilitates Codification updates for technical corrections such as conforming amendments, clarifications to guidance, simplifications to wording or the structure of guidance, and other minor improvements. The amendments are effective for public business entities for fiscal years beginning after December 15, 2024, with early adoption permitted. Early application of the amendments in this ASU is permitted for all entities, for any fiscal year or interim period for which financial statements have not yet been issued (or made available for issuance). If an entity adopts the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. The Company ishas ~~currently~~determined ~~assessing~~that the ~~effect~~impact of this ASU on its consolidated financial statements and related disclosures is immaterial.

4. Estimates and Judgments

The preparation of financial statements in conformity with US GAAP requires us to make certain estimates, judgments and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amount of revenue and expenses during the fiscal period. Some of the Company’s accounting policies require us to make subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. These accounting policies involve critical accounting estimates because they are particularly dependent on estimates and assumptions made by management about matters that are highly uncertain at the time the accounting estimates are made. Although we have used our best estimates based on facts and circumstances available to us at the time, different estimates reasonably could have been used. Changes in the accounting estimates used by the Company are reasonably likely to occur from time to time, which may have a material effect on the presentation of financial condition and results of operations.

Table of Contents

Management reviews our estimates, judgments, and assumptions periodically and reflects the effects of any revisions in the period in which they are deemed to be necessary. We believe that these estimates are reasonable. However, actual results could differ from these estimates.

5. Accounts and Other Receivables

Accounts receivable as of ~~February~~May 2831, 2026 and August 31, 2025 consist of the following:

	Feb. 28, 2026		August 31,2025
	May 31, 2026		August 31,2025
Territory license fees	$	-	$	174,000
Sales tax		4248,~~029~~998		194,358
Long term receivable		64,014		64,013
Total Receivables	$	~~106~~113,~~043~~012	$	432,371

6. Prepaid Expenses and Other Current Assets

Prepaid expenses consist of the following as of ~~February~~May 2831, 2026 and August 31, 2025:

	Feb. 28,		August 31,
	May 31,		August 31,
	2026		2025
Advertising & Conferences	$	~~182~~10,~~031~~531	$	1,572
Research & Development		58251,~~416~~861		669,791
Legal & Accounting Fees		26,487		37,340
License, Filing Fees, Dues		6648,~~458~~333		27,563
Office & Insurance		~~108~~54,~~440~~747		239,829
Consulting		176,~~014~~806		37,409
Capital Financing		-		119,000
Total Prepaid Expenses and Other Current Assets	$	~~458~~398,~~846~~765	$	1,132,504

7. Intellectual Property, net

A continuity schedule for capitalized patents is presented below:

	Feb. 28,			August 31,
	May 31,			August 31,
	2026			2025
Balance – beginning	$	307,818		$	516,676
Additions		2046,~~193~~445			75,106
Impairment		-			(247,364	)
Amortization		(915,~~953~~247	)		(36,600	)
Balance – ending	$	~~318~~339,~~058~~016		$	307,818

~~The~~During the nine months ended May 31, 2026, the Company ~~evaluated~~reviewed its patent portfolio to ~~determine~~identify ~~whether certain~~ pending applications that had been abandoned or ~~will~~that management does not beintend ~~pursued~~to pursue. ~~During~~As ~~the~~a ~~six~~result ~~months~~of ~~ended~~this ~~February 28~~review, ~~2026,~~no ~~the Company recognized an~~ impairment loss ofwas ~~$0 related to those abandoned applications~~recognized. The Company recognized $915,~~953~~247 of amortization expense related to patents ~~and~~for ~~licenses in~~ the ~~six~~nine months ended ~~February~~May 2831, 2026.

Table of Contents

The following table summarizes expected future amortization of the Company’s patent portfolio as of ~~February~~May 2831, 2026:

Fiscal Years Ending August 31,
2026 (six months remaining)	$	7,951
2026 (three months remaining)	$	4,238
2027		1516,~~902~~951
2028		1516,~~902~~951
2029		1516,~~902~~951
2030		1516,~~902~~951
Thereafter		~~246~~266,~~499~~974
Total	$	~~318~~339,~~058~~016

8. Property & Equipment, net

Consists of:

February 28, 2026	Cost		Period Amortization			Additions		Accumulated Amortization			Net Balance
May 31, 2026	Cost		Period Amortization			Additions		Accumulated Amortization			Net Balance
Leasehold improvements	$	259,981	$	-		$	-	$	(259,981	)	$	-
Computers		70,781		-			-		(70,781	)		-
Furniture fixtures equipment		31,126		-			-		(31,126	)		-
Lab equipment		435,084		(2639,~~014~~928	)		40,816		(~~232~~246,~~969~~883	)		~~242~~229,~~931~~017
Total	$	796,972	$	(2639,~~014~~928	)	$	40,816	$	(~~594~~608,~~857~~771	)	$	~~242~~229,~~931~~017

August 31, 2025	Cost		Period Amortization			Additions		Accumulated Amortization			Net Balance
Leasehold improvements	$	259,981	$	-		$	-	$	(259,981	)	$	-
Computers		70,781		(1,705	)		-		(70,781	)		-
Furniture fixtures equipment		31,126		-			-		(31,126	)		-
Lab equipment		410,438		(49,520	)		24,646		(206,955	)		228,129
Total	$	772,326	$	(51,225	)	$	24,646	$	(568,843	)	$	228,129

Depreciation and amortization related to property and equipment for the ~~six~~nine months ended ~~February~~May 2831, 2026 and the year ended August 31, 2025 totaled $2639,~~014~~928 and $51,225, respectively, of which $0 and $0 was included in cost of goods sold, respectively.

9. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities as of ~~February~~May 2831, 2026 and August 31, 2025 consist of the following:

	February 28,		August 31,
	May 31,		August 31,
	2026		2025
Accounts Payable
Vendors payable	$	36104,~~195~~612	$	569,754
Sales tax payable		2822,~~629~~987		21,506
Accrued Liabilities
Vendors payable		7109,~~707~~528		795,290
Vacation payable		~~110~~113,~~080~~250		76,496
Balance Ending	$	~~182~~350,~~611~~377	$	1,463,046

Table of Contents

10. Revenues

A breakdown of our revenues by type for the ~~six~~nine months ended ~~February~~May 2831, 2026, and ~~February~~May 2831, 2025, are as follows:

	Six months EndedFebruary 28
	Nine months EndedMay 31
	2026		2025
IP Licensing	$	20,000	$	~~348~~522,000
B2B		-		9,923
Total	$	20,000	$	~~357~~531,923

The Company recognized $20,000 and $~~348~~522,000 in licensing revenue for the ~~six~~nine months ended ~~February~~May 2831, 2026, and ~~February~~May 2831, 2025, respectively. Licensing revenue consists of IP licensing fees for transfer of the DehydraTECH technology in line with definitive agreements and includes non-refundable minimum performance fees. During the ~~six~~nine-month period ended ~~February~~May 2831, 2026, and ~~February~~May 2831, 2025, the Company recognized B2B product revenues of $0 and $9,923, respectively, that relate to sales of our intermediate products for use by B2B customers in their products.

11. Income Taxes

For the ~~six~~nine months ended ~~February~~May 2831, 2026, the Company recognized a provision for income taxes of $4,~~389~~403 for its Kelowna Management Services Corp. subsidiary. Net deferred tax assets are fully offset by a valuation allowance as the Company believes it is more likely than not that the benefit will not be realized.

12. Stockholders' Equity

During the ~~six~~nine months ended ~~February~~May 2831, 2026, the Company completed the following issuances of common shares and warrants:

On September 26, 2025, the Company, pursuant to a Securities Purchase Agreement, issued 2,666,667 shares of common stock at a purchase price of $1.50 per share for gross proceeds of $4.0 million. Share issuance costs of $0.65 million were charged to additional paid in capital. The shares were registered pursuant to a take down of the Company’s Form S-3 registration statement. Concurrently, the Company issued 2,666,667 share purchase warrants, entitling the holders thereof to purchase up to 2,666,667 shares of common stock at a price of $1.37 per share for a period of five years from the effective date of the S-1 Registration Statement registering the shares of common stock issuable upon exercise of the warrants. We also issued H.C. Wainwright, the exclusive placement agent for the offering, warrants to purchase up to 93,333 shares at an exercise price of $1.875 per share. HCW was paid 7% of the gross proceeds and was reimbursed $70,000 for its expenses and $15,950 in closing fees.

On December 14, 2025, the Company, pursuant to a Securities Purchase Agreement, issued 2,661,600 shares of common stock at a purchase price of $1.315 per share for gross proceeds of $3.5 million. Share issuance costs of $0.5 million were charged to additional paid in capital. The shares were registered pursuant to a take down of the Company’s Form S-3 registration statement. Concurrently, the Company issued 2,661,600 share purchase warrants, entitling the holder thereof to purchase up to 2,661,600 shares of common stock at a price of $1.19 per share for a period of five years from the effective date of the S-1 Registration Statement registering the shares of common stock issuable upon exercise of the warrants. We also issued H.C. Wainwright, the exclusive placement agent for the offering, warrants to purchase up to 93,156 shares at an exercise price of $1.6438 per share. HCW was paid 7% of the gross proceeds and was reimbursed $70,000 for its expenses and $15,950 in closing fees.

A continuity schedule for warrants for the nine months ended May 31, 2026, is presented below:

	Number of Warrants		Weighted Average Exercise Price
Balance, August 31, 2025		7,298,171	$	3.75
Issued		5,514,756		1.30
Expired		1,719,828		6.58
Balance, May 31, 2026		11,093,099	$	2.09

Table of Contents

A ~~continuity~~summary ~~schedule~~of ~~for~~ warrants ~~for~~outstanding ~~the~~as ~~six~~of ~~months~~May ~~ended February 28~~31, 2026, is presented below:

Number of Warrants		~~Number of Warrants~~		Weighted Average Exercise Price		~~Weighted Average Exercise Price~~		Weighted Average RemainingContractual Life ~in years~
Balance, August 31, 2025			7,298,171			$	3.75
	483,750			$	0.95				1.95
Issued			5,514,756				1.30
	314,287				2.31				2.72
Expired			1,719,828				6.58
	102,097				5.94				2.72
Balance, February 28, 2026			11,093,099			$	2.09
	4,551,019				3.06				3.63
	57,190				3.83				3.63
	70,000				1.25				3.90
	2,760,000				1.39				4.52
	2,754,756				1.21				4.62
	11,093,099			$	2.09				3.99

A summary of warrants outstanding as of February 28, 2026, is presented below:

Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life ~in years~
	483,750	$	0.95		2.20
	314,287		2.31		2.97
	102,097		5.94		2.97
	4,551,019		3.06		3.88
	57,190		3.83		3.88
	70,000		1.25		4.15
	2,760,000		1.39		4.77
	2,754,756		1.21		4.88
	11,093,099	$	2.09		4.24

Stock Options

The Company established an Equity Incentive Plan whereby our Board, pursuant to shareholder approved amendments, may grant up to 2,488,744 stock options, restricted stock awards or restricted stock units to directors, officers, employees, and consultants with such number being increased to up to 10% of the issued share capital at the end of each calendar year, at the discretion of the board, pursuant to an evergreen formula.

Stock options currently granted must be exercised within five years from the date of grant or such lesser period as determined by the Company’s board of directors. The vesting terms of each grant are also set by the board of directors. The exercise price of an option is equal to or greater than the closing market price of the Company’s common shares on the date of grant.

A continuity schedule for stock options is presented below:

	Options			WeightedAverageExercisePrice		WeightedAverageRemaining ContractualTerm(years)		AggregateIntrinsicValue
Balance August 31, 2024		944,936		$	3.11		3.64	$	971,959
Cancelled/expired		(47,001	)		7.78		0.75		-
Granted		586,500			1.41		4.84		-
Balance August 31, 2025		1,484,435		$	2.29		3.49	$	206
Cancelled/expired		(8129,~~400~~900	)	$	2.8498		-		-
Granted		-45,000			-0.65		-4.94		-
Balance February 28, 2026 (outstanding)		1,476,035		$	2.29		3.00	$	-
Balance May 31, 2026 (outstanding)		1,399,535		$	2.17		2.96	$	-
Balance February 28, 2026 (exercisable)		1,368,851		$	2.19		2.96	$	-
Balance May 31, 2026 (exercisable)		1,317,805		$	2.09		2.94	$	-

The Company granted 45,000 stock options with an exercise price of $0.65 and a term of five years to certain consultants and scientific advisory board members during the nine months ended May 31, 2026. The fair value of the options amounted to $18,975 and was determined using the Black-Scholes option pricing model with the following assumptions:

May 31, 2026
Expected volatility		106	%
Risk-free interest rate		3.93	%
Expected life	2.50 years
Dividend yield		0.00	%
Estimated fair value per option	$	0.42

Stock-based compensation expense for the nine-month periods ended May 31, 2026, and May 31, 2025, totaled $242,734 and $736,770, respectively.

Table of Contents

~~The~~As ~~Company~~of ~~did~~May ~~not~~31, ~~grant~~2026, ~~any~~the total unrecognized non-cash compensation costs are $177,363 related to 81,730 non-vested stock options ~~during~~with ~~the~~a ~~six~~$3.41 ~~months~~weighted ~~ended~~average ~~February~~exercise ~~28,~~price. ~~2026~~These costs are expected to be recognized over a weighted average period of 0. 5 years.

~~Stock-based~~Return ~~compensation~~of ~~expense for the six-month periods ended February 28, 2026, and February 28, 2025, totaled $149,790 and $266,634, respectively.~~ Shares

AsOn ofMarch ~~February 28~~17, 2026, the ~~total~~100,000 ~~unrecognized~~shares ~~non-cash~~previously ~~compensation~~issued ~~costs are $237,567 related~~ to ~~107,184~~the ~~non-vested~~Company’s ~~stock~~Strategic ~~options~~Executive ~~with~~Consultant under a ~~$3.44~~Restricted ~~weighted~~Stock ~~average~~Award ~~exercise~~were ~~price.~~gifted ~~These~~back ~~costs are expected~~ to bethe ~~recognized~~Company ~~over~~and ~~a weighted average period of 0~~cancelled.~~8 years.~~

13. Commitments, Significant Contracts and Contingencies

Right of Use Assets - Operating Lease

The corporate office and R&D laboratory are located in Kelowna, British Columbia, Canada. The related lease was renewed until November 15, 2028. In addition to minimum lease payments, the lease requires us to pay property taxes and other operating costs which are subject to annual adjustments.

	February 28,2026			August 31, 2025
	May 31,2026			August 31, 2025
Right of use assets - operating leases	$	106,816		$	134,843
Amortization		(1422,~~798~~401	)		(28,027	)
Total lease assets	$	9284,~~018~~415		$	106,816
Liabilities:		109,319			137,366
Lease payments		(1828,~~672~~009	)		(37,094	)
Interest accretion		35,~~739~~403			9,047
Total lease liabilities	$	9486,~~386~~714		$	109,319
Operating lease cost	$	92,018		$	106,816
Total operating lease cost	$	84,415		$	106,816
Operating cash flows for lease	$	(1828,~~672~~009	)	$	(37,094	)
Remaining lease term	2.7146 Years			3.21 Years
Discount rate		7.25	%		7.25	%

Pursuant to the terms of the Company’s lease agreements in effect, the following table summarizes the Company’s maturities of operating lease liabilities as of ~~February~~May 2831, 2026:

2026	$	189,~~672~~336
2027		38,642
2028		38,901
2029		8,104
Thereafter		-
Total lease payments		~~104~~94,~~319~~983
Less: imputed interest		(98,~~933~~269	)
Present value of operating lease liabilities		9486,~~386~~714
Less: current obligations under leases		(3233,~~060~~035	)
Total	$	6253,~~326~~679

Table of Contents

14. Segment Information

The Company has one reportable segment: IP licensing. The IP licensing segment generates revenue from customers by licensing its proprietary DehydraTECH technology.

The IP licensing segment's accounting policies are the same as those described in the summary of significant accounting policies at Note 2.

The chief operating decision maker, our Chief Executive Officer, assesses performance of the IP Licensing segment and makes resource allocation decisions based on cash flows that are also reported on the Consolidated Statements of Cash Flows.

The measure of segment assets is reported on the balance sheet as consolidated total assets.

The measure of segment profit or loss is net loss as per the Consolidated Statements of Operations and Comprehensive Loss.

The Company invested in additions to intellectual property and purchases of equipment totaling $2046,~~193~~445 and $40,816, respectively, during the ~~six~~nine months ended ~~February~~May 2831, 2026, and $4160,~~052~~496 and $24,~~646~~645, respectively during the ~~six~~nine months ended ~~February~~May 2831, 2025.

	Six Months EndedFebruary 28,
	Nine months EndedMay 31,
IP Licensing Segment	2026			2025
Licensing revenue	$	20,000		$	~~348~~522,000
less:
Research and Development		12,~~146~~117,~~728~~562			36,~~639~~356,~~136~~637
Consulting		~~184~~333,~~834~~355			~~319~~453,~~016~~690
Wages & Salaries		~~774~~1,~~032~~086,706			~~685~~1,~~657~~468,759
Legal and professional		~~352~~483,~~521~~164			~~241~~295,~~976~~252
Accounting and audit		~~160~~178,~~043~~299			~~144~~154,~~583~~638
Advertising and promotions		20279,~~852~~467			~~328~~388,~~824~~128
Depreciation and amortization		3555,~~960~~166			3566,~~470~~426
Office and miscellaneous (a)		~~345~~466,~~734~~828			~~335~~454,~~272~~739
Travel		1828,~~140~~691			3450,~~085~~171
Impairment Loss		-			33,540
Other income (loss)		(2019,~~312~~475	)		18(22,~~119~~066	)
Segment net loss	$	(35,~~039~~028,~~156~~713	)	$	(59,~~431~~222,~~440~~046	)
Reconciliation of profit and loss:
B2B revenue		-			9,923
less:
B2B cost of sales		-			2,720
B2B operating expenses		610,~~690~~100			(637	)
Consolidated net loss before income taxes	$	(35,~~045~~038,~~846~~813	)	$	(59,~~423~~214,~~600~~206	)

(a) Office and miscellaneous expense includes office expense, foreign currency exchange gains and losses, ~~bad debt,~~ and other overhead expenses.

15. Subsequent Events

On March 17, 2026, the 100,000 shares previously issued to the Company’s Strategic Executive Consultant under a Restricted Stock Award were gifted back to the Company, cancelled, and returned to treasury.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

This quarterly report contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained herein that are not statements of historical fact may be forward-looking statements. These statements relate to future events or our future financial performance. Any forward-looking statements are based on our present beliefs and assumptions as well as the information currently available to us. In some cases, forward-looking statements are identified by terminology such as “may”, “will”, “should”, “could”, “targets”, “goal”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks in the section entitled “Risk Factors” set forth in Item 1(A) and in our annual report on Form 10-K, as filed with the Securities and Exchange Commission on November 28, 2025, that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We caution you not to place undue reliance on any forward-looking statements as they speak only as of the date on which such statements were made, and we undertake no obligation to update any forward-looking statement or to reflect the occurrence of an unanticipated event. New factors may emerge, and it is not possible to predict all factors that may affect our business and prospects. Further, management cannot assess the impact of each factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Our unaudited interim consolidated financial statements are stated in United States Dollars (“US$”) and are prepared in accordance with United States Generally Accepted Accounting Principles (“US GAAP”). The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in US$. All references to “common shares” and “shares” refer to the common shares in our capital stock, unless otherwise indicated. The terms “Lexaria” “we”, “us”, “our” and “Company” mean the Company and/or our subsidiaries, unless otherwise indicated.

The following discussion should be read in conjunction with our condensed financial statements and accompanying notes in this quarterly report on Form 10-Q, and our audited financial statements with notes in our annual report on Form 10-K for the year ended August 31, 2025.

Company Overview

Lexaria’s DehydraTECH patented technology is a drug delivery platform technology that improves the way that Active Pharmaceutical Ingredients (“API”) enter the bloodstream and brain tissue. Based on R&D studies completed in animals and humans, DehydraTECH has been shown to improve the delivery of bioactive compounds into the bloodstream, offering potential to lower overall dosing, and is highly effective in API delivery available in a range of formats from oral ingestible to oral buccal/sublingual to topical products. DehydraTECH substantially improves the rapidity and quantity of API transport to the blood plasma and brain using the body’s natural process for distributing fatty acids via oral ingestion. This technology extends across many categories beyond the primary pharmaceutical focus of the Company, from foods and beverages to cosmetic products and nutraceuticals.

20 Table of Contents

Research & Development Summary

Lexaria is advancing its preclinical R&D activities as well as planned future clinical programs. During the ~~six~~nine months ended ~~February~~May 2831, 2026, Lexaria:

· Completed final data collection, via its wholly owned subsidiary, Lexaria (AU) Pty Ltd, for its Australian Phase 1b 12-week chronic clinical study (GLP-1-H24-4) of DehydraTECH formulated cannabidiol and semaglutide (separately and in combination) and tirzepatide in overweight or obese, or pre- and Type II diabetic participants. Subsequently, in December 2025, the Company announced findings from this study indicating that it met its primary endpoint objectives showing good safety and tolerability of all DehydraTECH test articles with clear reductions in total and gastrointestinal-specific adverse events relative to the Rybelsus® control arm. The Study demonstrated positive findings across numerous parameters with comparability, and in some instances, superiority to the Rybelsus® control arm; · Announced the extension of the Material Transfer Agreement (“MTA”) through April 30, 2026 originally entered into with a pharmaceutical company (“PharmaCO”) on September 4, 2024. The extension provides PharmaCO with the time required for receipt and review of the full dataset from Lexaria’s Australian study, at which time further information will be provided. This allows the two parties to continue their relationship under the MTA, keep the temporary exclusive license active and in force, and contemplate additional strategic planning discussions with PharmaCO’s human clinical development team; and · Announced positive final results from its GLP-1-H25-5 Human Pilot Study comparing oral DehydraTECH enhanced liraglutide (“DHT-LIR”) to the commercially available injected Saxenda® liraglutide. These results demonstrated achievement of the primary safety and tolerability endpoint for DHT-LIR, comparable functionality of DHT-LIR and Saxenda® and comparable efficacy. · Announced information on three new studies from its 2026 R&D Program which are representative of the Company’s primary areas of focus during for the fiscal year (see MD&A Research & Development section below).

Table of Contents

	·	Announced the extension of the Material Transfer Agreement (“MTA”) through December 30, 2026 originally entered into with a pharmaceutical company (“PharmaCO”) on August 30, 2024. The extension provides PharmaCO with the time required for receipt and review of the full dataset from Lexaria’s GLP-1-H26-7 pilot study, at which time further information will be provided. This allows the two parties to continue their relationship under the MTA, keep the temporary exclusive license active and in force, and contemplate additional strategic planning discussions with PharmaCO’s human clinical development team; and

	·	Announced positive final results from its GLP-1-H25-5 Human Pilot Study comparing oral DehydraTECH enhanced liraglutide (“DHT-LIR”) to the commercially available injected Saxenda® liraglutide. These results demonstrated achievement of the primary safety and tolerability endpoint for DHT-LIR, comparable functionality of DHT-LIR and Saxenda® and comparable efficacy.

	·	Announced information on three new studies from its 2026 R&D Program, including the receipt of ethics board approval for its Human Pilot Study #7 (GLP-1-H26-7), the engagement of the contract research organization for each of its two GLP-1 animal studies, Animal Study #1 (GLP-1-A26-1) and Animal Study #2 (GLP-1-A26-2), and, shortly after May 31, the completion of dosing in Animal Study #2 which are representative of the Company’s primary areas of focus during for the fiscal year (see MD&A Research & Development section below).

Financings

During the ~~six~~nine months ended ~~February~~May 2831, 2026, the Company entered into a Securities Purchase Agreement whereby on:

· On September 29, 2025, the Company issued 2,666,667 shares of common stock at a purchase price of $1.50 per share for gross proceeds of $4.0 million. Share issuance costs of $0.65 million were charged to additional paid in capital. The shares were registered pursuant to a take down of the Company’s Form S-3 registration statement. Concurrently, the Company issued 2,666,667 share purchase warrants, entitling the holders thereof to purchase up to 2,666,667 shares of common stock at a price of $1.37 per share for a period of five years from the effective date of the S-1 Registration Statement registering the shares of common stock issuable upon exercise of the warrants. We also issued H.C. Wainwright, the exclusive placement agent for the offering, warrants to purchase up to 93,333 shares at an exercise price of $1.875 per share. HCW was paid 7% of the gross proceeds and was reimbursed $70,000 for its expenses and $15,950 in closing fees. On December 14, 2025, the Company issued 2,661,600 shares of common stock at a purchase price of $1.315 per share for gross proceeds of $3.5 million. Share issuance costs of $0.5 million were charged to additional paid in capital. The shares were registered pursuant to a take down of the Company’s Form S-3 registration statement. Concurrently, the Company issued 2,661,600 share purchase warrants, entitling the holder thereof to purchase up to 2,661,600 shares of common stock at a price of $1.19 per share for a period of five years from the effective date of the S-1 Registration Statement registering the shares of common stock issuable upon exercise of the warrants. We also issued H.C. Wainwright, the exclusive placement agent for the offering, warrants to purchase up to 93,156 shares at an exercise price of $1.6438 per share. HCW was paid 7% of the gross proceeds and was reimbursed $70,000 for its expenses and $15,950 in closing fees.

21 Table of Contents

Patents

Our current patent portfolio includes patent family applications or grants pertaining to Lexaria’s compositions, methods of use in improving API bioavailability and palatability and methods of treatment for a range of therapeutic indications, orally or topically, for a wide variety of APIs encompassing GLP-1~~/GIPs~~, GIP, and glucagons; fat soluble vitamins; NSAID pain medications; nicotine and its analogs; and cannabinoids. The pending and granted patents also cover the manufacturing and processing methods used to combine a variety of fatty acid-rich triglyceride oils with active pharmaceutical ingredients. This includes heating and drying methods and use of excipients and substrates.

~~The~~21 ~~Company~~Table ~~currently has several applications pending worldwide and due to the complexity~~ of pursuing patent protection, the quantity of patent applications will vary continuously as each application advances or stalls. We continue to investigate national and international opportunities to pursue expansions and additions to our intellectual property portfolio. Patents have been filed or granted specifically for the use of DehydraTECH with GLP-1/GIP drugs to support our ongoing and expanding cardiometabolic clinical research programs in this therapeutic field for the treatment of diabetes/weight loss. Patents have been filed or granted specifically for the use of DehydraTECH with cannabinoids for the treatment of heart disease and hypertension to support our anticipated clinical trial work under our cleared Investigational New Drug (“IND”) application with the Food and Drug Administration (“FDA”), and for treatment of other prospective therapeutic indications of interest to us including epilepsy.Contents

The Company currently has several applications pending worldwide and due to the complexity of pursuing patent protection, the quantity of patent applications will vary continuously as each application advances or stalls. We continue to investigate national and international opportunities to pursue expansions and additions to our intellectual property portfolio. Patents have been filed or granted specifically for the use of DehydraTECH with GLP-1, GIP, and glucagon drugs to support our ongoing and expanding cardiometabolic clinical research programs in this therapeutic field for the treatment of diabetes/weight loss. Patents have been filed or granted specifically for the use of DehydraTECH with cannabinoids for the treatment of heart disease and hypertension to support our anticipated clinical trial work under our cleared Investigational New Drug (“IND”) application with the Food and Drug Administration (“FDA”), and for treatment of other prospective therapeutic indications of interest to us including epilepsy.

We will continue to seek beneficial acquisitions of intellectual property if and when we believe it is advisable to do so. Due to the inherent unpredictability of scientific discovery, it is not possible to predict if or how often such new applications might be filed, or patents issued.

22 Table of Contents

Below we summarize Lexaria’s granted patents.

Issued Patent #	Patent Grant Date	Patent Family
US 9,474,725 B1	10/25/2016	#1 Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof
US 9,839,612 B2	12/12/2017
US 9,972,680 B2	05/15/2018
US 9,974,739 B2	05/22/2018
US 10,084,044 B2	09/25/2018
US 10,103,225 B2	10/16/2018
US 10,381,440	08/13/2019
US 10,374,036	08/06/2019
US 10,756,180	08/25/2020
AU 2015274698	06/15/2017
AU 2017203054	08/30/2018
AU 2018202562	08/30/2018
AU 2018202583	08/30/2018
AU 2018202584	01/10/2019
AU 2018220067	07/30/2019
EP 3164141	11/11/2020
JP 6920197	07/28/2021
CDN 2949369	06/13/2023
EP 3858364	09/17/2025
AU 2016367036	07/30/2019	#2 Methods for Formulating Orally Ingestible Compositions Comprising Lipophilic Active Agents
JP 6963507	10/19/2021
MX 388 203 B	11/26/2021
AU 2016367037	08/15/2019	#3 Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents
IN 365864	04/30/2021
JP 6917310	07/21/2021
MX 390001	02/10/2022
JP 7232853	02/22/2023
CDN 2984917	09/26/2023
CDN 3093414	12/13/2022	#6 Transdermal and/or Dermal Delivery of Lipophilic Active Agents
EP 3765088	03/20/2024
JP 7112510	07/26/2022	#7 Lipophilic Active Agent Infused Compositions with Reduced Food Effect
AU 2019256805	06/16/2022	#8 Compositions Infused with Nicotine Compounds and Methods of Use Thereof
CDN 3096580	05/23/2023
CDN 3111082	08/29/2023	#14 Lipophilic Active Agent Infused Tobacco Leaves and/or Tobacco Materials and Methods of Use Thereof
US 11,311,559	04/26/2022	#18 Compositions and Methods for Enhanced Delivery of Antiviral Agents
AU 2021261261	03/23/2023
JP 7415045	01/05/2024
CDN 3172889	05/28/2024
AU 2023200736	10/02/2025

Table of Contents

AU 2016367036	07/30/2019	#2 Methods for Formulating Orally Ingestible Compositions Comprising Lipophilic Active Agents
JP 6963507	10/19/2021
MX 388 203 B	11/26/2021
AU 2016367037	08/15/2019	#3 Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents
IN 365864	04/30/2021
JP 6917310	07/21/2021
MX 390001	02/10/2022
JP 7232853	02/22/2023
CDN 2984917	09/26/2023
CDN 3093414	12/13/2022	#6 Transdermal and/or Dermal Delivery of Lipophilic Active Agents
EP 3765088	03/20/2024
JP 7112510	07/26/2022	#7 Lipophilic Active Agent Infused Compositions with Reduced Food Effect
AU 2019256805	06/16/2022	#8 Compositions Infused with Nicotine Compounds and Methods of Use Thereof
CDN 3096580	05/23/2023
CDN 3111082	08/29/2023	#14 Lipophilic Active Agent Infused Tobacco Leaves and/or Tobacco Materials and Methods of Use Thereof
US 11,311,559	04/26/2022	#18 Compositions and Methods for Enhanced Delivery of Antiviral Agents
AU 2021261261	03/23/2023
JP 7415045	01/05/2024
CDN 3172889	05/28/2024
AU 2023200736	10/02/2025
US 11,700,875	07/18/2023	#20 Compositions and Methods for Sublingual Delivery of Nicotine
CDN 3196911	12/05/2023
JP 7675819	05/01/2025
AU 2023240953	01/15/2026
US 11,666,544	06/06/2023	#21 Compositions and Methods for Treating Hypertension
US 11,666,543	06/06/2023
US 11,980,593	05/14/2024
EP 4326249	10/15/2025
JP 7823051	02/20/2026
JP 7823052	02/20/2026

Table of Contents

US 11,700,875	07/18/2023	#20 Compositions and Methods for Sublingual Delivery of Nicotine
CDN 3196911	12/05/2023
JP 7675819	05/01/2025
AU 2023240953	01/15/2026
US 11,666,544	06/06/2023	#21 Compositions and Methods for Treating Hypertension
US 11,666,543	06/06/2023
US 11,980,593	05/14/2024
EP 4326249	10/15/2025
JP 7823051	02/20/2026
JP 7823052	02/20/2026
US 11,931,369	03/19/2024	#24 Compositions and Methods for Treating Epilepsy
US 11,944,635	04/02/2024
US 11,986,485	05/21/2024
US 12,023,346	07/02/2024
US 12,213,986	02/04/2025
US 12,220,422	02/11/2025
AU 2024202447	06/12/2025
AU 2024202475	07/24/2025
AU 2024202439	01/08/2026
AU 2024202518	01/08/2026
EP 4522133	01/14/2026
AU 2024205127	02/12/2026
US 12,397,042	08/26/2025	#27 Compositions and Methods for Treating Diabetes
US 12,472,236	11/18/2025
AU 2025205229	02/12/2026
AU 2024394427	02/12/2026

24 Table of Contents

Research & Development

The Company regularly pursues new R&D programs that investigate potential commercial applications for the incorporation of DehydraTECH. These include, but are not limited to, ongoing programs to explore different therapeutic indications which DehydraTECH-enhanced drug products can be utilized to treat. Currently, our primary clinical research areas of interests are focused on the investigation of DehydraTECH-powered GLP-1/, GIP, and glucagon drugs as well as CBD for the treatment of diabetes and weight loss and, also, CBD for the reduction of hypertension for which our IND application to perform a Phase 1b study received a Study May Proceed letter from the FDA in early calendar-2024. Previously, our study programs provided successful human and/or animal testing results with DehydraTECH formulations of nicotine for oral pouches and prospective nicotine replacement therapy, human hormones, antiviral drugs, CBD for hypertension, diabetes, weight loss, seizure disorder applications, and others. Depending on the number or complexity of the programs undertaken, R&D budgets are expected to vary significantly. It is in our best interest to remain flexible at this early stage of our R&D efforts in order to capitalize on potential novel findings from early-stage tests and, thus, redirect research when necessary into specific avenues that offer the most reward.

~~Chronic~~24 ~~Dosing~~Table ~~Human~~of ~~Study (GLP-1-H24-4)~~Contents

~~During~~Human ~~the~~Pilot ~~quarter~~Study ~~ended~~#7 ~~February 28, 2026, Lexaria via its wholly owned subsidiary, Lexaria~~ (~~AU) Pty Ltd, completed the close-out and data analysis activities for its Australian clinical study (~~GLP-1-~~H24~~H26-47), with its CRO service provider, Novotech (Australia) Pty Limited. GLP-1-H24-4 investigated DehydraTECH formulated cannabidiol and semaglutide alone or in combination, as well as DehydraTECH formulated tirzepatide, in overweight or obese or pre- and Type II diabetes participants. Participant enrolment for all five arms of study GLP-1-H24-4 resulted in the dosing of 100+ participants. In December 2025, the Company announced findings from this study indicating that it met its primary endpoint objectives showing good safety and tolerability of all DehydraTECH test articles with clear reductions in total and gastrointestinal-specific adverse events relative to the Rybelsus® control arm. The Study demonstrated positive findings across numerous parameters with comparability, and in some instances, superiority to the Rybelsus® control arm.

~~Management~~During ~~has assessed~~ the ~~Company’s~~quarter ~~research~~ended ~~and~~May ~~development~~31, ~~activities~~2026, ~~and~~Lexaria ~~expenditures~~engaged toits ~~determine~~contract ~~which~~research ~~activities~~organization (“CRO”) and ~~expenditures~~received ~~are~~ethics ~~likely~~board toapproval ~~be eligible~~ for ~~the~~this ~~Australian~~5-week ~~research~~parallel ~~and~~group ~~development~~design ~~incentive~~study ~~described~~intended into ~~Note~~evaluate 2the ~~above~~safety, tolerability and ~~has~~pharmacokinetic ~~submitted~~(“PK”) anproperties ~~application~~of ~~for~~two ~~the~~oral ~~credit~~DehydraTECH-semaglutide ~~with~~compositions ~~respect~~against tosemaglutide ~~eligible~~tablets ~~expenditures~~commercially ~~incurred~~sold ~~during~~under the ~~fiscal~~Wegovy® ~~year~~brand. The ~~ended~~DehydraTECH-semaglutide ~~August~~compositions ~~31,~~being ~~2025.~~investigated are:

Human Pilot Study #5 (GLP-1-H24-5)

(1)	A DehydraTECH-semaglutide tablet formulated to mimic Novo Nordisk’s® Rybelsus® and Wegovy® oral semaglutide tablets which incorporate salcaprozate sodium (“SNAC”) and are designed to temporarily adhere to the stomach lining and disintegrate and dissolve releasing agents in a focal manner that aids in optimizing absorption of the semaglutide into the human body; and

(2)	A DehydraTECH-semaglutide capsule, as previously investigated by Lexaria (AU) Pty Ltd in our Phase 1b clinical trial (GLP-1-H24-4) performed in Australia, but with the addition of SNAC as was also the case in our previous successful clinical study GLP-1-H24-1.

~~During~~Results ~~the quarter ended February 28, 2026, Lexaria with its third-party bioanalytical service providers completed its pharmacokinetic (“PK”) blood liraglutide quantitation and profiling results~~ from this study. ~~This~~are ~~included~~anticipated ~~the use of two different manufactured brands of commercially available ELISA (enzyme-linked immunosorbent assay) test kits. Due~~ to ~~challenges encountered with background signal noise detection (believed to~~ be ~~attributable~~released toduring the ~~fact~~second ~~that~~quarter liraglutide and other peptide drugs are commonly known to bind with, and have poor separation from, albumin; a naturally occurring protein present in human blood plasma) that complicated the ability to accurately capture blood liraglutide measurements in both the Saxenda® and DHT-LIR study samples, results were limited to exploratory visualization of ~~the~~fiscal ~~raw~~year ~~ELISA signals which, nonetheless, over time demonstrated broadly similar temporal patterns~~2027. ~~The visualization of the similar signal patterns of the two treatments is consistent with the instances of functional comparability otherwise demonstrated in the study.~~

~~The~~Animal ~~two~~Study ~~most~~#1 ~~important strategic objectives of this study were:~~(GLP-1-A26-1)

1During –the Toquarter ~~discover~~ended ~~whether~~May ~~the~~31, ~~DehydraTECH~~2026, ~~processing~~Lexaria ofengaged ~~liraglutide~~its ~~would~~CRO ~~work~~to ~~sufficiently~~perform ~~enough~~an toanimal ~~potentially~~study ~~allow~~ for anthe ~~oral~~purposes ~~version~~ of ~~the~~evaluating ~~drug~~between 8 to be11 ~~compared~~formulation enhancements to the ~~current~~DehydraTECH-semaglutide ~~injection~~and DehydraTECH-~~only~~CBD ~~delivery~~formulations, ~~method;~~previously ~~and~~studied in Lexaria (AU) Pty Ltd’s Phase 1b clinical trial performed in Australia, in Sprague-Dawley rats over a 24-hour period.

2In –addition Toto ~~demonstrate~~quantifying ~~that~~the ~~oral~~PK ~~DHT~~performance of each enhanced composition of DehydraTECH-~~LIR~~semaglutide ~~could~~and ~~produce~~DehydraTECH-CBD ~~comparable~~against ~~functional~~its ~~results~~applicable reference arm, Lexaria also intends to measure the ~~injected~~drug ~~version,~~concentrations ~~allowing~~of ~~for~~semaglutide anand ~~expedited~~CBD ~~FDA~~in ~~regulatory~~the ~~development~~brain ~~pathway~~to ~~known~~determine asif athe ~~505(b)(2)~~DehydraTECH ~~new~~technology ~~drug~~enhances ~~application~~brain ~~that~~biodistribution isas ~~available~~it ~~when~~has anevidenced ~~alternate~~in ~~version~~previous ofanimal astudies ~~drug~~with ~~(e.g.,~~DehydraTECH-CBD ~~the~~and ~~dosage~~DehydraTECH-semaglutide ~~form~~compositions, ~~change~~which ~~from~~it ~~injection~~believes to ~~oral~~be ~~administration~~beneficial astherapeutically. ~~tested~~Results ~~within~~from this ~~Study)~~study ~~retains~~are ~~certain~~anticipated ~~similar~~to ~~performance~~be ~~characteristics~~released asduring anthe ~~earlier-approved~~fourth ~~version~~quarter of ~~that~~fiscal ~~same~~year ~~drug~~2026.

~~Both~~Animal ofStudy ~~these~~#2 ~~objectives were successfully accomplished, while also evidencing tolerability advantages of DHT~~(GLP-~~LIR over Saxenda® from a user appeal perspective.~~1-A26-2)

During the quarter ended May 31, 2026, Lexaria engaged its CRO and commenced the single dose treatment regimen of the animals with DehydraTECH-enhanced retatrutide and amycretin with the expectation of completing between 14 to 18 different arms of dosing to determine formulation optimization. This will be the first investigation of DehydraTECH with retatrutide and amycretin with the study arms also comparing PK performance of test articles administered both endoscopically in the intestine as compared to being swallowed, thus targeting the stomach. On June 9, 2026, Lexaria announced that dosing had been completed in Animal Study #2. Results from this study are anticipated to be released during the fourth quarter of fiscal year 2026.

Long Term Stability Testing

Lexaria also routinely studies the chemical and microbiological purity and stability of select DehydraTECH compositions that it has prepared for its animal and human studies over an extended duration of 6-12 months. Along with improved tolerability, PK and efficacy performance, long term stability is crucial if oral variants of GLP-1, / GIP and glucagon drugs are to be seriously considered as replacements for currently injectable versions of these drugs. Stability findings thus far are positive and meeting internal expectations.

25 Table of Contents

Hypertension Phase 1b IND Trial HYPER-H23-1

The FDA provided Lexaria with a positive written response on August 10, 2022, from our pre-IND meeting regarding DehydraTECH-CBD for the treatment of hypertension. The FDA confirmed that it had agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway for our program. On January 29, 2024, Lexaria submitted its IND application with the FDA and it received a Study May Proceed letter from the FDA on February 29, 2024. Since that time, Lexaria iscontinues ~~attending~~to attend to its annual reporting update obligations to the FDA for study HYPER-H23-1 to maintain its active status and continues to address certain of the FDA conditions while also seeking funding to commence the study.

Table of Contents

The IND application was supported by the results of Lexaria’s five investigator-initiated human clinical studies of its DehydraTECH-CBD which were conducted between 2018-2023, in an aggregate total of 134 people, without recording a single serious adverse event (the “HYPER Studies”). The HYPER Studies evidenced significant reductions in resting blood pressure over both acute and multi-week dosing regimens alone and, in some cases, complementary to standard of care medications; suggesting that DehydraTECH-CBD has the potential to have broad therapeutic utility.

Of note, DehydraTECH-CBD was evaluated recently in Lexaria (AU) Pty Ltd’s Australian clinical study GLP-1-H24-4, with findings announced in December 2025, in overweight or obese, or pre- and Type II diabetic participants. It was noteworthy therein that the DehydraTECH-CBD arm achieved meaningful reductions in blood pressure supportive of ~~the Company’s~~ hypertension treatment interests, even though study GLP-1-H24-4 was pursued to assess formulations for distinct potential therapeutic use in the fields of diabetes and weight loss management. At week 4 of treatment in study GLP-1-H24-4, a mean change of −4.6 mmHg in systolic blood pressure and −4.0 mmHg in diastolic blood pressure was evidenced in the DehydraTECH-CBD arm. Blood pressure reductions were also evident in this arm following completion of treatment at the week 16 follow up point (4 weeks after cessation of treatment) with a mean change of −2.6 mmHg in systolic blood pressure and −3.0 mmHg in diastolic blood pressure reported.

FY26 Research and Development Program

The Company’s 2026 research and development program is designed to broaden pharmaceutical, intellectual property, and business development opportunities through new and improved formulations. It includes the following:

· A five-week parallel group human study consisting of three different arms with primary goals of establishing safety and tolerability, as well as pharmacokinetic evaluation, comparing salcaprozate sodium (“SNAC”)-inclusive DehydraTECH-semaglutide tablet and capsule formulations to the recently launched, commercially available Wegovy® semaglutide tablets under fasted pre-dose conditions. · Animal studies designed to establish scientific evidence supporting new concepts, procedures and formulations intended to facilitate the development of new intellectual property through the development and filing of patent applications; and to test wide varieties of conditions and formulations to narrow down choices prior to potential future corroborating human study work.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.

Critical Accounting Policies and Estimates

Our consolidated financial statements and accompanying notes are prepared in accordance with US GAAP. These accounting principles require management to make certain estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses during the periods reported. Based on information available to management at the time, these estimates, judgments and assumptions are considered reasonable. We believe that understanding the basis and nature of the estimates, judgments and assumptions involved with the following aspects of our financial statements is critical to an understanding of our financials.

A critical accounting estimate is an accounting estimate for which a) the nature of the estimate is material due to the related level of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change, and b) the impact of the estimate on the Company’s financial position or operating performance is material. We did not identify any such estimates in our Annual Report on Form 10-K for the year ended August 31, 2025 and none have been identified for the ~~six~~nine months ended ~~February~~May 2831, 2026.

26 Table of Contents

Funding Requirements

We anticipate that our expenditures in connection with our ongoing R&D program will continue, specifically with respect to our animal and human clinical trials of our DehydraTECH formulations for the purposes of our investigations with GLP-1 drugs and treating hypertension. As we move forward with our planned R&D studies, we anticipate that we will continue to incur operating losses and negative cash flows for the foreseeable future covering 2026 and beyond.

Through ~~February~~May 2831, 2026, we have funded our operations primarily through the proceeds from the sale of common stock. The Company has consistently incurred recurring losses and negative cash flows from operations, including net losses of $35,~~050~~043,~~235~~216 and $59,~~423~~214,~~600~~206 for the ~~six~~nine months ended ~~February~~May 2831, 2026, and ~~February~~May 2831, 2025, respectively.

During the ~~six~~nine months ended ~~February~~May 2831, 2026, we raised $6.5 million in net proceeds from the sale of securities pursuant to our Registered Direct offerings which closed in September, 2025 and December, 2025.

Table of Contents

The continuation of Lexaria as a going concern depends on raising additional capital and/or attaining and maintaining profitable operations. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern within one year following the date that these consolidated financial statements on Form 10-Q are filed and do not include any adjustment relating to the recovery and classification of recorded asset amounts or the amount and classification of liabilities that might be necessary should our Company discontinue operations. The Company expects that its current cash resources will be sufficient to fund the Company’s operations through the first quarter of fiscal year 2027. However, management has also concluded that given the Company’s current cash position, recurring losses from operations and net capital deficiency, there is substantial doubt as to the Company’s ability to continue as a going concern within one year following the date that these consolidated financial statements are issued.

Results of Operations for the Period Ended ~~February~~May 2831, 2026, and ~~February~~May 2831, 2025

Our net loss for the ~~six~~nine months ended for the respective items are summarized as follows:

	February 28,			February 28,
	May 31,			May 31,
	2026			2025			Change
Revenue	$	20,000		$	~~357~~531,923		$	(~~337~~511,923	)
Cost of goods sold		-			(2,720	)		2,720
Research & development		(12,~~146~~117,~~728~~562	)		(36,~~639~~356,~~136~~637	)		24,~~492~~239,~~408~~075
Consulting fees & salaries		(~~958~~1,~~866~~420,061	)		(1,~~004~~922,~~672~~449	)		45502,~~806~~388
Legal and professional		(~~512~~661,~~564~~463	)		(~~386~~449,~~559~~890	)		(~~126~~211,~~005~~573	)
Other general & administrative		(~~427~~840,~~376~~252	)		(~~766~~992,~~555~~367	)		~~339~~152,~~179~~115
Other income (loss)		(2019,~~312~~475	)		18(22,~~119~~066	)		~~(38~~2,~~431~~591	)
Net loss before income taxes	$	(35,~~045~~038,~~846~~813	)	$	(59,~~423~~214,~~600~~206	)	$	24,~~377~~175,~~754~~393

Revenue

Fees from intellectual property licensing and B2B sales totaled $20,000 and $~~357~~531,923, respectively, for the ~~six~~nine-month periods ended ~~February~~May 2831, 2026 and ~~February~~May 2831, 2025. For the ~~six~~nine months ended ~~February~~May 2831, 2026, relative to the ~~six~~nine months ended ~~February~~May 2831, 2025, license fees and B2B sales decreased by $~~328~~502,000 and $9,923, respectively, reflecting the expiration of the Premier Anti-Aging Co., Ltd. licensing contract and a continuing shift in emphasis away from pursuit of B2B clients as we move toward pharmaceuticals. The Company did not recognize any other revenue during the ~~six~~nine months ended ~~February~~May 2831, 2026 or the ~~six~~nine months ended ~~February~~May 2831, 2025.

27 Table of Contents

Research and Development

Expenditures on R&D decreased by $24,~~492~~239,~~408~~075 year-over-year for the ~~six~~nine-month period ended ~~February~~May 2831, 2026, as we completed our Phase 1b Clinical Trial (GLP-1-H24-4) in December of 2025. Lexaria continues with applied ~~development~~research ~~and~~& development programs in our pharmaceutical division with our primary focus being on optimization of DehydraTECH formulations of GLP-1 drugs, as well as advancing our DehydraTECH-CBD drug to treat hypertension.

Consulting Fees and Salaries

In the ~~six~~nine months ended ~~February~~May 2831, 2026, consulting fees and salaries decreased by $45502,~~806~~388 year-over-year, primarily due to lower stock-based compensation ($~~116~~494,~~744~~037) and the discontinuation of certain consulting arrangements ($~~134~~120,~~182~~335); partially offset by higher incentive compensation ($131,071) and salary adjustments ($74,150) .

Table of Contents

Legal and Professional Fees

Our legal and professional fees increased by $~~126~~211,~~005~~573 during the ~~six~~nine months ended ~~February~~May 2831, 2026 as compared to the same prior year period due to higher accounting and professional fees associated with registration statement filings, financing activities and ~~the~~ utilization of patent-related legal ~~advisory~~ services.

General and Administrative

Our other general and administrative expenses decreased in total by $~~339~~152,~~179~~115 during the ~~six~~nine-month period ended ~~February~~May 2831, 2026, as compared to the same prior year period. The decrease is primarily attributable to lower spending on advertising and promotions ($~~307~~108,~~972~~661) and decreased impairment losses ($33,540).

Liquidity and Financial Condition

Working Capital	~~February~~May 2831,			August 31,
	2026			2025
Current assets	$	54,~~770~~064,~~282~~869		$	3,468,345
Current liabilities		(~~214~~383,~~671~~412	)		(1,493,463	)
Net working capital	$	53,~~555~~681,~~611~~457		$	1,974,882

Cash Flows	~~February~~May 2831,			~~February~~May 2831,
	2026			2025
Cash flows used in operating activities	$	(34,~~147~~782,~~970~~990	)	$	(47,~~223~~807,~~936~~889	)
Cash flows used in investing activities		(5986,~~008~~097	)		(6585,~~698~~141	)
Cash flows provided by financing activities		6,518,105			46,~~357~~046,~~113~~163
Effect of exchange rate changes on cash		1423,~~891~~862			(9861,~~430~~257	)
Net change in cash for the period	$	31,~~326~~672,~~018~~880		$	(301,~~951~~908,124	)

Operating Activities

Net cash used in operating activities was approximately $34.18 million for the ~~six~~nine months ended ~~February~~May 2831, 2026, compared with $47.28 million during the same prior year period. The decrease is attributable to a decrease of $2.4.2 million in our net loss, partially offset by ana ~~increase~~decrease in operating assets and liabilities of $10.26 million as we completed Study GLP-1-H24-4, and a decrease of $0.15 million in non-cash expenses.

28 Table of Contents

Investing Activities

Net cash used in investing activities was $5986,~~008~~097 for the ~~six~~nine months ended ~~February~~May 2831, 2026, compared to $6585,~~698~~141 for the same prior year period. The decrease relates primarily to lower spending on the prosecution of intellectual property, partially offset by increased purchases of laboratory equipment.

Financing Activities

Net cash from financing activities was approximately $6.5 million for the ~~six~~nine months ended ~~February~~May 2831, 2026, compared to approximately $46.40 million for the same prior year period. The increase relates to higher net proceeds from the sale of common shares.

Liquidity and Capital Resources

Since inception, the Company has incurred significant operating and net losses. Net losses attributable to shareholders were $35.0 million and $59.42 million for the ~~six~~nine months ended ~~February~~May 2831, 2026, and ~~February~~May 2831, 2025, respectively. As of ~~February~~May 2831, 2026, we had an accumulated deficit of $6668.5 million. We expect to continue to incur significant operational expenses and net losses in the upcoming 12 months. Our net losses may fluctuate significantly from quarter to quarter and year to year, depending on the stage and complexity of our R&D studies and corporate expenditures, additional revenues received from the licensing of our technology, if any, and the receipt of payments under any current or future collaborations into which we may enter. The recurring losses and negative net cash flows raise substantial doubt as to the Company’s ability to continue as a going concern.

Table of Contents

Sources of Liquidity

During the ~~six~~nine months ended ~~February~~May 2831, 2026, the Company has completed the following:

	·	Entered into a Securities Purchase Agreement whereby on September 29, 2025, the Company issued 2,666,667 shares of common stock at a purchase price of $1.50 per share for gross and net proceeds of $4.0 million and $3.45 million, respectively. Concurrently, the Company issued, by way of a private placement transaction, 2,666,667 share purchase warrants, entitling the holder thereof to purchase up to 2,666,667 shares of common stock at a price of $1.37 per share for a period of five years from the effective date of the S-1 Registration Statement registering the warrant shares. The shares registered pursuant to a take down of the Company’s Form S-3 registration statement and the warrants and related warrant shares were registered pursuant to a Form S-1 registration statement. We also issued the placement agent warrants to purchase up to 93,333 shares for a period of five years from the date of issuance at an exercise price of $1.875 per share.
	·	Entered into a Securities Purchase Agreement whereby on December 14, 2025, the Company issued 2,661,600 shares of common stock at a purchase price of $1.315 per share for gross and net proceeds of $3.5 million and $3.0 million, respectively. Concurrently, the Company issued, by way of a private placement transaction, 2,661,600 share purchase warrants, entitling the holder thereof to purchase up to 2,661,600 shares of common stock at a price of $1.19 per share for a period of five years from the effective date of the S-1 Registration Statement registering the warrant shares. The shares registered pursuant to a take down of the Company’s Form S-3 registration statement and the warrants and related warrant shares were registered pursuant to a Form S-1 registration statement. We also issued the placement agent warrants to purchase up to 93,156 shares for a period of five years, at an exercise price of $1.6438 per share.

We may also offer securities in response to market conditions or other circumstances if we believe such a plan of financing is required to advance the Company’s business plans. There is no certainty that future equity or debt financing will be available or that it will be at acceptable terms and the outcome of these matters is unpredictable. A lack of adequate funding may force us to reduce spending, curtail or suspend planned programs or possibly liquidate assets. Any of these actions could adversely and materially affect our business, cash flow, financial condition, results of operations, and potential prospects. The sale of additional equity may result in additional dilution to our stockholders. Entering into additional licensing agreements, collaborations, partnerships, alliances marketing, distribution, or licensing arrangements with third parties to increase our capital resources is also possible. If we do so, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us.

29 Table of Contents

Going Concern

The accompanying unaudited consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the ordinary course of business. As of ~~February~~May 2831, 2026, the Company had cash and cash equivalents of approximately $53.15 million to settle $0.24 million in current liabilities. We have performed a review of our cash flow forecast, and given our current development plans and cash management efforts, we anticipate that our cash resources will be sufficient to fund operations through the first quarter of fiscal year 2027. However, we have also concluded that our existing cash, combined with inflows expected from executed license agreements, will not be sufficient to meet the Company's financial obligations for the twelve-month period following the issuance of these consolidated financial statements. Accordingly, there is substantial doubt as to our ability to continue as a going concern for at least one year following the date of the financial statements included in this quarterly report. We intend to fund operations, working capital and other cash requirements for the twelve-month period subsequent to ~~February~~May 2831, 2026 through equity financing arrangements and potentially from collaborations or strategic partnerships.

Table of Contents

The successful outcome of future activities cannot be determined at this time and there is no assurance that, if achieved, we will have sufficient funds to execute our intended business plan or generate positive operating results.

The consolidated financial statements do not include any adjustments related to this uncertainty and as to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result should we be unable to continue as a going concern.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

Item 4. Controls and Procedures

Management’s Report on Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our President, our Chief Executive Officer (Principal Executive Officer) and our Chief Financial Officer (Principal Financial and Accounting Officer) to allow for timely decisions regarding required disclosure.

As of ~~February~~May 2831, 2026, the fiscal quarter covered by this report, we carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of ~~February~~May 2831, 2026.

Inherent limitations on Effectiveness of Controls

Internal control over financial reporting has inherent limitations which include but are not limited to the use of independent professionals for advice and guidance, interpretation of existing and/or changing rules and principles, regulations, segregation of management duties, scale of organization, and personnel factors. It is a process which involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. It can be circumvented by collusion or improper management override. Internal control over financial reporting may not prevent or detect misstatements on a timely basis. These inherent limitations are known features of the financial reporting process, and it is possible to design into the process safeguards to reduce, though not eliminate, these risks. Systems determined to be effective can provide only reasonable assurances with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Changes in Internal Control over Financial Reporting

During the quarter ended ~~February~~May 2831, 2026, our controls and controls processes remained consistent with those in effect at August 31, 2025. There have been no changes in our internal controls over financial reporting that occurred during the quarter ended ~~February~~May 2831, 2026, that have materially or are reasonably likely to materially affect our internal controls over financial reporting.

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

We are not party to any material, pending or existing legal proceedings against our Company or its subsidiaries, nor are we involved as a plaintiff in any other material proceeding or pending litigation. There are no proceedings in which any of our directors, executive officers or affiliates, or any registered or beneficial stockholder, is an adverse party or has a material interest adverse to our interest.

Item 1A. Risk Factors

Much of the information included in this quarterly report includes or is based upon estimates, projections or other "forward-looking statements". Such forward-looking statements include any projections or estimates made by us and our management in connection with our business operations. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein.

The risks associated with our business, common stock and other factors are those described below and in our Form 10-K for the year ended August 31, 2025, as filed with the SEC on November 28, 2025.

In the event that we fail to satisfy any of the listing requirements of the Nasdaq Capital Market, our common stock may be delisted, which could affect our market price and liquidity.

Our common stock is listed on the Nasdaq Capital Market. For continued listing on the Nasdaq Capital Market, we will be required to comply with the continued listing requirements, including the minimum market capitalization standard, the corporate governance requirements and the minimum closing bid price requirement, among other requirements. On February 4, 2026, we received a deficiency letter from the Nasdaq Listings Qualifications Department notifying us that, for the last 30 consecutive business days, the bid price for our common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market. We have been provided with a 180-day compliance period or until August 3, 2026, in which to regain compliance, which could potentially be extended by Nasdaq for an additional 180 days so long as we are otherwise in compliance with all listing requirements. If we do not achieve compliance with the minimum bid rule by August 3, 2026, we intend to request an additional 180-day compliance period from Nasdaq. As we are currently in compliance with all other listing requirements, we expect to receive the additional 180-day compliance period, during which time we will determine what actions, if any, are needed to regain compliance with the minimum bid price requirement. Such actions may include effecting a reverse stock split if we are unable to regain compliance with the minimum bid price requirement. Even if a reverse stock split is effected, there can be no assurance that we will maintain compliance with the minimum bid price requirement, or that we will continue to be in compliance with the other continued listing requirements of the Nasdaq Capital Market.

In the event that we fail to regain compliance with the minimum bid price requirement, we fail to obtain a second compliance period from Nasdaq, or we fail to satisfy any of the other listing requirements of the Nasdaq Capital Market, our common stock may be delisted. If our securities are delisted from trading on the Nasdaq Capital Market, and we are not able to list our securities on another exchange, our securities could be quoted on the OTC Bulletin Board or on the “pink sheets.” As a result, we could face significant adverse consequences including:

· a limited availability of market quotations for our securities; · a determination that our common stock is a “penny stock,” which would require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;

Table of Contents

·In athe ~~limited~~event ~~amount~~that ofwe ~~news~~fail ~~and~~to ~~analyst~~regain ~~coverage;~~compliance ·with athe ~~limited~~minimum ~~ability~~bid toprice ~~raise~~requirement, ~~equity~~we ~~capital~~fail to ~~continue~~obtain a second compliance period from Nasdaq, or we fail to ~~fund~~satisfy any of the other listing requirements of the Nasdaq Capital Market, our ~~research~~common ~~and~~stock ~~development~~may ~~programs;~~be delisted. If our securities are delisted from trading on the Nasdaq Capital Market, and ·we aare ~~limited~~not ~~ability~~able to ~~acquire~~list ~~other~~our ~~companies~~securities oron ~~technologies~~another byexchange, ~~using~~ our ~~shares~~securities ascould ~~consideration~~be quoted on the OTC Bulletin Board or on the “pink sheets.” As a result, we could face significant adverse consequences including:

	·	a limited availability of market quotations for our securities;
	·	a determination that our common stock is a “penny stock,” which would require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;
	·	a limited amount of news and analyst coverage;
	·	a limited ability to raise equity capital to continue to fund our research and development programs; and
	·	a limited ability to acquire other companies or technologies by using our shares as consideration.

Item 2. Recent Sales of Unregistered Equity Securities

During the ~~six~~nine months ended ~~February~~May 2831, 2026, the Company issued:

	·	2,666,667 share purchase warrants with an exercise price of $1.37 that expire on December 9, 2030 to purchase up to 2,666,667 shares of common stock;
	·	93,333 placement agent share purchase warrants with an exercise price of $1.875 that expire on September 26, 2030 to purchase up to 93,333 shares of the common stock;
	·	2,661,600 share purchase warrants with an exercise price of $1.19 that expire on January 14, 2031 to purchase up to 2,661,600 shares of common stock; and
	·	93,156 placement agent share purchase warrants with an exercise price of $1.6438 that expire on December 16, 2030 to purchase up to 93,156 shares of the common stock.

Item 3. Rule 10b5-1 Trading Plans

Our Insider Trading Policy provides that our insiders, employees and consultants may enter into trading plans to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. During the fiscal quarter ended ~~February~~May 2831, 2026, none of the Company’s insiders had entered into a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (as such terms are defined in Item 408(a) of Regulation S-K of the Securities Act of 1933).

Table of Contents

Item 4. Exhibits, Financial Statement Schedules

a) Financial Statements

1) Financial statements for our Company are listed in the index under Item 1 of this document.

2) All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the financial statements or notes thereto.

32 Table of Contents

b) Exhibits

Exhibit Number		Description
(3)		Articles of Incorporation and Bylaws
3.1		Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed January 14, 2021)
3.2		Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed January 14, 2021)
(4)		Instruments Defining the Rights of Security Holders
4.1		Form of Private Placement Warrant (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed September 29, 2025)
4.2		Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed September 29, 2025)
4.3		Form of Private Placement Warrant (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed December 16, 2025)
4.4		Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed December 16, 2025)
(10)		Material Contracts
10.1		Form of Securities Purchase Agreement dated September 26, 2025 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed September 29, 2025)
10.2		Form of Securities Purchase Agreement dated December 14, 2025 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed December 16, 2025)
(31)		Rule 13(a) - 14 (a)/15(d) - 14(a)
31.1		Section 302 Certifications under Sarbanes-Oxley Act of 2002 of Principal Executive Officer
31.2		Section 302 Certifications under Sarbanes-Oxley Act of 2002 of Principal Financial Officer and Principal Accounting Officer
(32)		Section 1350 Certifications
32.1		Section 906 Certification under Sarbanes Oxley Act of 2002 of Principal Executive Officer
32.2		Section 906 Certification under Sarbanes Oxley Act of 2002 of Principal Financial Officer and Principal Accounting Officer
(101)**		Interactive Data Files
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

** Furnished herewith. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of any registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, and otherwise are not subject to liability under those sections.

Table of Contents

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LEXARIA BIOSCIENCE CORP.

By: /s/ Richard Christopher Richard ChristopherChief Executive Officer (Principal Executive Officer)Date: ~~April~~July 13, 2026

In accordance with the Exchange Act, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By:	/s/ Richard Christopher
Richard ChristopherChief Executive Officer(Principal Executive Officer) Date: April 13, 2026
	Richard ChristopherChief Executive Officer(Principal Executive Officer) Date: July 13, 2026
By:	/s/ Michael Shankman
Michael ShankmanChief Financial Officer (Principal Financial and Accounting Officer)Date: April 13, 2026
	Michael ShankmanChief Financial Officer (Principal Financial and Accounting Officer)Date: July 13, 2026

Filing Compare · Lexaria Bioscience Corp.